She has considerable experience with system delivery reform and value-based payment models; life sciences reimbursement involving coding, coverage, payment, and drug pricing issues for innovative new technologies; and legal and regulatory issues before the U.S. Department of Health & Human Services (HHS) Office of the General Counsel.
Erin joined Foley Hoag from the CMS Division of the HHS Office of the General Counsel, where she was the lead attorney for the Center for Medicare and Medicaid Innovation (CMMI). While at HHS, Erin’s views on CMMI’s authority were widely viewed as authoritative, informing healthcare transformation and the expenditure of billions of appropriated dollars. In advising on dozens of CMMI’s innovative payment and service-delivery models, Erin also achieved extensive expertise in drafting value-based arrangements, Medicare and Medicaid coverage and reimbursement, the Administrative Procedure Act, and data privacy.
Prior to joining HHS, Erin served as the Director of Health Law and Policy at the Biotechnology Industry Organization (BIO). While at BIO, Erin worked with member companies from across the biotechnology industry to craft the industry's response to legislative and regulatory proposals on Medicare and Medicaid coverage and payment, alternative payment models, and government price reporting programs. She also gained a nationwide reputation as a leading expert on the 340B Drug Pricing Program, speaking on the topic at numerous conferences nationwide and prompting the Medicare Payment Advisory Commission (MedPAC) to seek her review of its 2015 Report to Congress titled “Overview of the 340B Drug Pricing Program.”